The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Large Is The Antibody Drug Conjugates Market Projected To Become By 2030 Based On Its 2026 Valuation?
The antibody drug conjugates market size has seen remarkable growth in recent years. It is anticipated to increase from $16.53 billion in 2025 to $20.28 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 22.7%. The expansion observed in the past can be attributed to the increasing prevalence of cancer, advancements in monoclonal antibody technology, a growing adoption of targeted therapies, an increase in clinical trials for oncology drugs, and supportive regulatory frameworks.
The antibody drug conjugates market is projected to experience rapid expansion in the coming years. By 2030, this market is anticipated to reach a valuation of $46.95 billion, expanding at a compound annual growth rate (CAGR) of 23.3%. Factors driving this growth during the forecast period include an increasing need for personalized medicine, the creation of innovative ADCs with enhanced safety, the incorporation of artificial intelligence into drug discovery, market expansion into developing regions, and collaborations between biotechnology and pharmaceutical firms. Key trends expected over the forecast horizon involve optimizing targeted drug delivery, innovating new linkers and payloads, employing combination therapies alongside immunotherapy, broadening the scope of oncology applications, and devising personalized approaches to cancer treatment.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2569&type=smp
Which Market Drivers Are Supporting The Expansion Of The Antibody Drug Conjugates Market?
A rise in clinical trial studies is anticipated to drive growth in the antibody drug conjugates market in the foreseeable future. Clinical trials are defined as research investigations where individuals voluntarily participate to evaluate novel treatments, interventions, or diagnostic tests aimed at preventing, detecting, treating, or managing diverse diseases or health conditions. Antibody-drug conjugates have become a prominent class of anti-cancer medicines, with a rapidly expanding number of them currently undergoing clinical trials for addressing both blood-related cancers and solid tumors. For example, data from December 2024, provided by the Association of the British Pharmaceutical Industry (ABPI), a UK trade body, indicates an increase in the total number of industry clinical trials launched in the UK, rising from 411 trials in 2022 to 426 in 2023. Consequently, the expanding volume of clinical trial studies is a key driver for the antibody drug conjugates market.
What Segment Groups Are Identified Within The Antibody Drug Conjugates Market?
The antibody drug conjugates market covered in this report is segmented –
1) By Type: Monoclonal Antibodies, Linker, Drug/Toxin, Other Types
2) By Product Brand: Adcertis, Kadcyla, Other Product Brands
3) By Technology: Immunogen Technology, Seattle Genetics Technology, Immunomedics Technology, Other Technology
4) By Application: Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor, Other Applications
5) By End User: Hospital, Clinics, Other End Users
Subsegments:
1) By Monoclonal Antibodies: IgG-based Monoclonal Antibodies, IgM-based Monoclonal Antibodies, Bispecific Antibodies
2) By Linker: Cleavable Linkers, Non-cleavable Linkers, Stable Linkers
3) By Drug/Toxin: Cytotoxic Drugs, Chemotherapeutic Agents, Radioisotopes
4) By Other Types: Enzyme-Targeted ADCs, Antibody-Drug Conjugates with Immune Modulators
What Trends Are Advancing Progress In The Antibody Drug Conjugates Market?
Leading companies involved in antibody-drug conjugate production are introducing innovative breakthrough conjugates, such as the first single-use reactor specifically designed for manufacturing antibody-drug conjugates (ADCs). This inaugural single-use reactor, crafted for ADC manufacturing, enables faster, more flexible, and contamination-free production of these targeted cancer treatments by eliminating the need for cleaning and sterilization between batches. For instance, in September 2024, Merck & Co., Inc., a US-based pharmaceutical company, launched the Mobius ADC reactor. Addressing the growing need for enhanced efficiency and safety in ADC manufacturing processes, this novel reactor tackles the specific challenges of ADC production, delivering a 70% boost in efficiency while considerably lowering the risks of cross-contamination and the labor-intensive cleaning associated with traditional stainless steel or glass reactors. The Mobius ADC Reactor utilizes Ultimus Film technology, which improves bag strength, durability, and leak resistance, thereby ensuring superior product quality.
Which Companies Hold Significant Positions In The Antibody Drug Conjugates Market?
Major companies operating in the antibody drug conjugates market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Millennium Pharmaceuticals Inc., Gilead Sciences Inc., Daiichi Sankyo Company Limited, Sorrento Therapeutics Inc., Astellas Pharma Inc., Seagen Inc., Synthon BV, Genentech Inc., ImmunoGen Inc., Nordic Nanovector ASA, ADC Therapeutics SA, Immunomedics Inc., Mersana Therapeutics Inc., Heidelberg Pharma AG, Celldex Therapeutics Inc., Oxford BioTherapeutics, Concortis Biotherapeutics Corp., Antikor BioPharma Ltd., Eisai Co. Ltd., Merck KGaA
Read the full antibody drug conjugates market report here:
https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report
How Is The Antibody Drug Conjugates Market Distributed Across Key Geographic Regions?
North America was the largest region in the antibody-drug conjugates (ADCs) market in 2025. The Middle East is expected to be the fastest-growing region in the global antibody drug conjugates market share during the forecast period. The regions covered in the antibody drug conjugates market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Antibody Drug Conjugates Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=2569&type=smp
Browse Through More Reports Similar to the Global Antibody Drug Conjugates Market 2026, By The Business Research Company
Antibody Drug Conjugates Market Report 2026
https://www.thebusinessresearchcompany.com/report/antibody-drug-conjugates-global-market-report
Next Generation Antibody Therapeutics Market Report 2026
Conjugate Vaccine Market Report 2026
https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model